for microcalcification, assessment of margins, fine needle aspiration biopsy and core biopsy, morphologic risk factors, predictive and prognostic factors, choice of biomarkers and standardization, pathology reports, second opinions and the associated costs and liabilities, and finally, the pathologist’s visibility in the medical community and breast cancer research.
Emphasis was also placed on the importance of the pathologist’s role in management and patient care as well as in the development of strategies to standardize the traditional as well as newly recognized technologies. It was generally agreed that The International Society of Breast Pathology should move toward becoming a companion society of The United States and Canadian division of The International Academy of Pathology. The focus, however, must be to create a working society to address the existing issues and to develop uniform guidelines in breast pathology.
It was suggested that the mission of The International Society of Breast Pathology can be achieved by enhanced communication and networking among pathologists, establishment of breast tissue banks and clinical follow-up data bases, initiation of consensus conferences, and providing educational opportunities and designing well-controlled, multinational and multidisciplinary breast cancer research studies.